Document is current
Any future updates will be listed below
-
Authors
Hardy, Janet R. https://orcid.org/0000-0003-1127-9951
Greer, Ristan M. https://orcid.org/0000-0002-1574-4729
Pelecanos, Anita M. https://orcid.org/0000-0003-0197-4504
Huggett, Georgie E.
Kearney, Alison M. https://orcid.org/0000-0002-3361-192X
Gurgenci, Taylan H. https://orcid.org/0000-0001-9695-9109
Good, Phillip D. https://orcid.org/0000-0002-8198-0375
-
Funding
Funding for this research was provided by:
Australian Government Medical Research Future Fund (APP1152232, APP2006191, APP1152232, APP2006191, APP1152232, APP2006191)
Mater Research Ltd
The University of Queensland
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 10 July 2025
First Online: 24 July 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Mater Human Research Ethics Committee (HREC/MML/49348) on 14/01/2019.
: Informed consent was obtained from all individual participants included in the study.
: JH and PG are recipients of two Australian Government Future Fund grants (MRFF APP 1152232 and 2006191) designed to study the role (if any) of medicinal cannabis in the symptom control of patients receiving palliative care. RG was paid for statistical services from these grants as was the salary of GH. PG has also received a Queensland Health Clinical Research Fellowship grant to progress these studies. JH received payment for research sessions from Mater Research Ltd. Medicinal cannabis and placebo were supplied free of charge from Little Green Pharma Ltd (LGP). LGP had no role in the design, running, analysis or publication of trial results. TG, AP and AK declare no competing interests.
